ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-47.51M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.05 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -30.32% |
| Return on Assets (Trailing 12 Months) | -27.87% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.85 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.85 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.73 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.11 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.54 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 82.11M |
| Free Float | 72.59M |
| Market Capitalization | $278.36M |
| Average Volume (Last 20 Days) | 1.23M |
| Beta (Past 60 Months) | 0.56 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 31.55% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |